<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062309</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000304712</org_study_id>
    <secondary_id>P30CA006927</secondary_id>
    <secondary_id>FCCC-02602</secondary_id>
    <nct_id>NCT00062309</nct_id>
  </id_info>
  <brief_title>Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer</brief_title>
  <official_title>A Phase III Intensity Modulated Radiotherapy Dose Escalation Trial for Prostate Cancer Using Hypofractionation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays and other sources of radiation to kill&#xD;
      tumor cells. It is not yet known which radiation therapy regimen is more effective in&#xD;
      treating prostate cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is comparing two different regimens of radiation&#xD;
      therapy to see how well they work in treating patients with stage II or stage III prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of conventional intensity-modulated radiotherapy (IMRT) vs&#xD;
           hypofractionated IMRT, in terms of freedom from biochemical failure in men with&#xD;
           intermediate- to high-risk prostate cancer.&#xD;
&#xD;
        -  Compare the local control, freedom from distant metastasis, and overall survival of&#xD;
           patients treated with these regimens.&#xD;
&#xD;
        -  Determine local failure, using biopsy of the prostate, when objective tests&#xD;
           (prostate-specific antigen, ultrasound, and digital rectal exam) suggest relapse in&#xD;
           these patients.&#xD;
&#xD;
        -  Compare the extent of disease eradication using biopsy of the prostate at 2 years after&#xD;
           therapy in these patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the impact of these regimens on patient preferences and utilities.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to pretreatment&#xD;
      prostate-specific antigen (no greater than 10 ng/mL vs greater than 10 to 20 ng/mL vs greater&#xD;
      than 20 ng/mL), Gleason score (5-7 vs 8-10), and risk status (high risk vs intermediate&#xD;
      risk). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo conventional intensity-modulated radiotherapy (IMRT) 5 days a&#xD;
           week for 7.5 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients undergo hypofractionated IMRT 5 days a week for 5 weeks in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with high-risk disease also undergo androgen deprivation therapy for 2 years.&#xD;
&#xD;
      Quality of life is assessed at baseline, every 6 months for 1 year, and then annually for 4&#xD;
      years.&#xD;
&#xD;
      Patients are followed at 3 months, every 6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this&#xD;
      study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from biochemical and/or disease failure rates</measure>
    <time_frame>weekly during treatment, at 3 months, 6 months or 2 years then yearly</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CIMRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>76 Gy in 38 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70.2 Gy in 26 fractions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>CIMRT</arm_group_label>
    <arm_group_label>HIMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Clinical stage T1b-T3c disease&#xD;
&#xD;
               -  No clinical or radiographic evidence of metastasis&#xD;
&#xD;
          -  Prostate-specific antigen (PSA) less than 80 ng/mL&#xD;
&#xD;
          -  Gleason score at least 5&#xD;
&#xD;
          -  One of the following criteria must be met:&#xD;
&#xD;
               -  PSA greater than 10 ng/mL&#xD;
&#xD;
               -  Gleason score greater than 6&#xD;
&#xD;
               -  T2b or greater palpable disease&#xD;
&#xD;
               -  Three or more biopsy cores involved with a Gleason score of at least 5&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except nonmetastatic skin cancer or&#xD;
             early stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic&#xD;
             leukemia)&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No more than 4 months of prior androgen deprivation therapy&#xD;
&#xD;
          -  Neoadjuvant and adjuvant androgen deprivation therapy is allowed for high-risk disease&#xD;
             only&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior or planned radical prostate surgery&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Buyyounouski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pollack A, Bae K, Khor LY, et al.: Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92-02 and Fox Chase randomized trials. [Abstract] Int J Biol Markers 22 (1): 72-3, 2006.</citation>
  </reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>March 1, 2016</last_update_submitted>
  <last_update_submitted_qc>March 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

